http://rdf.ncbi.nlm.nih.gov/pubchem/patent/GB-1115849-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_cec1f0aff18c0f523c702e3f4f221b45 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L2-0011 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-16 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61L2-00 |
| filingDate | 1967-03-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 1968-05-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | GB-1115849-A |
| titleOfInvention | Process for the preparation of a stable, hepatitis-virus free serum |
| abstract | Lipo-protein-free, hepatitis-virus-free, fibrinogen-free stable and sterile serum is prepared by intimately mixing blood serum or blood plasma with 250 to 545 mg of colloidal silicic acid per gram of total protein in the serum and, after separating the silicic acid containing lipoproteins and fibrinogen, irradiating the serum with U.V. light and then filtering sterile or vice versa. The process may be carried out at up to 50 DEG C. with a pH range of 6.5 to 8 and U.V. irradiation intensity of 1 milliwatt/cm2 minute. The sterile filtration is preferably interposed between the adsorbtion operation and the U.V. irradiation and may involve using asbestos-containing filters impervious to bacteria with a pore diameter of 0.9 to 1.2m or a milli pore sieve membrane with a pore diameter of 0.22m \sB 10%. The silicic acid precipitate may be treated with concentrated salt solutions in the alkaline pH range (preferably saturated Na Cl solution at pH 9.0) to obtain a lipoprotein solution. |
| priorityDate | 1966-04-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 21.